Bruce Alder Buckingham, MD
Pediatrics · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Buckingham’s office at (408) 885-5630 to ask if they take your plan before you enroll.
California Medical Board record
Licence G25563 · Current
Licensed to practise in California · since 1973 · expires 2028-02-29 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$62 in 2025
| 2025 | 1 | 1 | None | $62 |
| 2024 | 2 | 8 | $4,550 | $5,309 |
| 2023 | 1 | 28 | $7,475 | $9,809 |
| 2022 | 1 | 16 | $5,890 | $7,284 |
| 2021 | 3 | 17 | $11,545 | $12,433 |
| 2020 | 3 | 5 | $4,065 | $4,151 |
| 2019 | 7 | 30 | $16,195 | $20,188 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sequel Med Tech | Twiist | $62 | 1 payment
|
See the published payment
| Sequel Med Tech | Meals · 2025-09-29 | Twiist | $62 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,309
| Medtronic | Minimed 780g | $5,187 | 7 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $121 | 1 payment
|
2023: $9,809
| Medtronic | Minimed 780g | $9,809 | 28 payments
|
2022: $7,284
| Medtronic | Minimed 770g | $7,284 | 16 payments
|
2021: $12,433
| Novo Nordisk | Tresiba | $5,355 | 1 payment
|
| Medtronic | Minimed Quick-Set | $4,453 | 15 payments
|
| Lilly USA | None | $2,625 | 1 payment
|
2020: $4,151
| Medtronic MiniMed | None | $2,790 | 2 payments
|
| Insulet | Omnipod | $1,275 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump | $86 | 2 payments
|
2019: $20,188
| Medtronic MiniMed | Minimed 670g System | $14,175 | 24 payments
|
| Novo Nordisk AS | None | $2,295 | 1 payment
|
| Tandem Diabetes Care | T-Slim Insulin Pump | $2,000 | 1 payment
|
| ConvaTec | Aquacel Ag | $1,600 | 1 payment
|
| Eli Lilly and | None | $54 | 1 payment
|
| Senseonics | Eversense | $51 | 1 payment
|
| Dexcom | Dexcom Cgm | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Medtronic, Inc. · Cip321 Ahcl Pivotal Study · 2021 | Their institution | $397,251 |
| Insulet Corporation · Evaluating Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions With the Insulet Automated Glucose Control System: Ide3 · 2019 | Their institution | $344,088 |
| Insulet Corporation · Evaluating Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions With the Insulet Automated Glucose Control System: Ide3 · 2020 | Their institution | $285,235 |
| Medtronic MiniMed, Inc. · Cip321 Ahcl Pivotal Study · 2020 | Their institution | $248,553 |
| Medtronic MiniMed, Inc. · Hcl Pediatrics · 2019 | Their institution | $244,658 |
| Medtronic, Inc. · Cip321 Ahcl Pivotal Study · 2022 | Their institution | $235,258 |
| Insulet Corporation · Evaluating the Safety and Efficacy of the Omnipod 5 System Use Compared To Pump Therapy in the Treatment of Type 1 Diabetes: A Randomized, Parallel-Group Clinical Trial · 2022 | Their institution | $187,987 |
| Medtronic MiniMed, Inc. · Cep 304 670g Outcomes Study · 2019 | Their institution | $175,195 |
| Insulet Corporation · Evaluating the Safety and Effectiveness of the Omnipod Horizonautomated Insulin Delivery System in Patients With Type 1 Diabetes · 2021 | Their institution | $133,719 |
| Medtronic, Inc. · Cip321 Ahcl Pivotal Study · 2023 | Their institution | $117,025 |
| Medtronic MiniMed, Inc. · Cep 304 670g Outcomes Study · 2020 | Their institution | $96,392 |
| Insulet Corporation · Evaluating the Safety and Effectiveness of the Omnipod Horizonautomated Glucose Control System in Children With Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort · 2021 | Their institution | $81,571 |
| Medtronic MiniMed, Inc. · Cep294 Hcl · 2019 | Their institution | $76,401 |
| Medtronic MiniMed, Inc. · Cep298 Ewis · 2020 | Their institution | $76,021 |
| Medtronic MiniMed, Inc. · Cep302 Hcl Pediatrics · 2020 | Their institution | $67,474 |
| Medtronic MiniMed, Inc. · Cep302 Hcl Pediatrics · 2019 | Their institution | $58,373 |
| Medtronic MiniMed, Inc. · Investigator Sponsored Research · 2020 | Their institution | $57,550 |
| Medtronic, Inc. · Cep298 Ewis · 2021 | Their institution | $49,484 |
| Eli Lilly and Company · A Prospective, Randomized, Double-Blind Comparison of Ly900014 To Humalog With An Open-Label Postprandial Ly900014 Treatment Group in Children and Adolescents With Type 1 Diabetes · 2019 | Their institution | $31,661 |
| Insulet Corporation · Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients With Type 1 Diabetes · 2019 | Their institution | $13,424 |
| Medtronic, Inc. · Cep304 Hcl Outcomes Study · 2022 | Their institution | $12,099 |
| Medtronic, Inc. · Cep302 Hcl Pediatrics · 2021 | Their institution | $10,331 |
| Insulet Corporation · Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients With Type 1 Diabetes · 2019 | Their institution | $9,979 |
| Eli Lilly and Company · A Prospective, Randomized, Double-Blind Comparison of Ly900014 To Humalog With An Open-Label Postprandial Ly900014 Treatment Group in Children and Adolescents With Type 1 Diabetes · 2020 | Their institution | $9,080 |
| Medtronic, Inc. · Cep304 Hcl Outcomes Study · 2021 | Their institution | $7,062 |
| Novo Nordisk AS · Victoza · 2020 | Their institution | $3,310 |
| Medtronic, Inc. · Cip321 Ahcl Pivotal Study · 2024 | Their institution | $1,686 |
| Eli Lilly and Company · A Prospective, Randomized, Double-Blind Comparison of Ly900014 To Humalog With An Open-Label Postprandial Ly900014 Treatment Group in Children and Adolescents With Type 1 Diabetes · 2021 | Their institution | $1,600 |
| Novo Nordisk AS · Victoza · 2021 | Their institution | $1,039 |
| Medtronic MiniMed, Inc. · Cep294 Hcl · 2020 | Their institution | $1,000 |
| Medtronic, Inc. · Cep304 Hcl Outcomes Study · 2023 | Their institution | $256 |
Professional record
- NPI
- 1174560247
- Licence
- CA G25563California G25563: Current · expires 2028-02-29
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G255630
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 761 Matadero Ave, Palo Alto, CA, 94306
- NPI first listed
- 2006-05-31
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.